Composition, form of production and packaging
The tablets covered with a shell of greenish-yellow color, shining, round, biconcave.
1 tab.
components of the blood: deproteinized hemodereal blood of calves 200.0 mg,
in the form of AtoveginВ® granulate * 345.0 mg
* ActoveginВ® granulate contains: active substance: blood components: deproteinized hemoderivat of calves blood - 200.0 mg; auxiliary substances: povidone-K 90 - 10.0 mg, microcrystalline cellulose - 135.0 mg.
Excipients: magnesium stearate - 2.0 mg, talcum - 3.0 mg.
The composition of the shell: acacia gum - 6.8 mg, glycolic glax wax 0.1 mg, hypromellose phthalate 29.45 mg, diethyl phthalate 11.8 mg, dye quinoline yellow lacquer aluminum 2.0 mg, macrogol 6000 2.95 mg povidone-K 30 1.54 mg , sucrose - 52.3 mg, talc - 42.2 mg, titanium dioxide - 0.86 mg.
50 pcs. - bottles of dark glass (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2016.
PHARMACHOLOGIC EFFECT
The antihypoxant is a hemoderivat, which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5,000 daltons penetrate).
Positively affects the transport and utilization of glucose, stimulates oxygen consumption (which leads to stabilization of plasma cell membranes in ischemia and decreased lactate formation), which is the basis of antihypoxic action, which begins to manifest at the latest 30 minutes after ingestion and reaches a maximum on average after 3 hours (2-6 hours).
Actovegin В® increases the concentrations of ATP, ADP, phosphocreatine, as well as amino acids (glutamate, aspartate) and GABA.
The effect of ActoveginВ® on the assimilation and utilization of oxygen, as well as insulin-like activity with the stimulation of transport and glucose oxidation, are significant in the treatment of diabetic polyneuropathy.
In patients with diabetes and diabetic polyneuropathy, ActoveginВ® reliably reduces the symptoms of polyneuropathy (stitching, burning sensation, paresthesia, numbness of the lower limbs). Objective disorders are reduced sensitivity, mental well-being of patients improves.
PHARMACOKINETICS
With the help of pharmacokinetic methods it is impossible to study the pharmacokinetic characteristics (absorption, distribution, excretion) of active components of the drug Actovegin В® , since it consists only of the physiological components that are usually present in the body.
To date, there has been no reduction in the pharmacological efficacy of hemoderivatives in patients with altered pharmacokinetics (including liver or renal insufficiency, metabolic changes associated with advanced age, due to metabolic peculiarities in newborns).
INDICATIONS
- in the complex therapy of metabolic and cerebral disorders of the brain (various forms of cerebral circulatory insufficiency, dementia, craniocerebral trauma);
- peripheral (arterial and venous) vascular disorders and their consequences (angiopathy, trophic ulcers);
- diabetic polyneuropathy.
DOSING MODE
Assign inside the 1-2 tab. 3 times / day before meals. The tablet is not chewed, washed down with a small amount of water. Duration of treatment is 4-6 weeks.
With diabetic polyneuropathy, ActoveginВ® is administered iv in a dose of 2000 mg / day for 3 weeks, followed by a transition to taking the drug in the form of tablets - 2-3 tablets. 3 times / day for at least 4-5 months.
SIDE EFFECT
Allergic reactions: urticaria, swelling, drug fever.
CONTRAINDICATIONS
- Hypersensitivity to the components of the drug or to similar drugs.
With caution should prescribe the drug for heart failure II-III stage, pulmonary edema, oliguria, anuria, hyperhydration, during pregnancy and lactation.
PREGNANCY AND LACTATION
The use of ActoveginВ® during pregnancy and lactation is permitted, but caution should be exercised.
APPLICATION FOR FUNCTIONS OF THE LIVER
With caution should prescribe the drug for oliguria, anuria.
SPECIAL INSTRUCTIONS
When developing allergic reactions, taking Actovegin should be stopped. If necessary, a standard therapy for allergic reactions (antihistamines and / or SCS) is performed.
OVERDOSE
Information about the overdose of the drug Actovegin В® is not provided.
DRUG INTERACTION
Drug interaction of the drug Actovegin В® is not established.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of the reach of children, protected from light at a temperature of no higher than 25 В° C. Shelf life - 3 years. Do not use after expiry date.
